[{"id":"09261b2f-42ac-4b72-856f-4daf46603021","acronym":"NCI10208","url":"https://clinicaltrials.gov/study/NCT03816358","created_at":"2021-01-18T18:51:22.211Z","updated_at":"2024-07-02T16:35:03.288Z","phase":"Phase 1","brief_title":"Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer","source_id_and_acronym":"NCT03816358 - NCI10208","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • gemcitabine • anetumab ravtansine (BAY 94-9343) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 12/09/2019","start_date":" 12/09/2019","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-05-16"},{"id":"549a7364-24ed-4cb0-a1a5-48fe62ef459e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05804526","created_at":"2023-04-07T13:03:06.963Z","updated_at":"2024-07-02T16:35:07.029Z","phase":"Phase 1/2","brief_title":"A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours","source_id_and_acronym":"NCT05804526","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • misitatug blivedotin (RC88)"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 07/19/2023","start_date":" 07/19/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-30"},{"id":"75a6d88a-b107-4182-b4f0-b14a5142fd63","acronym":"","url":"https://clinicaltrials.gov/study/NCT04175847","created_at":"2021-01-29T07:19:59.914Z","updated_at":"2024-07-02T16:35:18.633Z","phase":"Phase 1/2","brief_title":"A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT04175847","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" MSLN","pipe":"","alterations":" ","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e misitatug blivedotin (RC88)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 04/14/2020","start_date":" 04/14/2020","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-02-20"},{"id":"1709c9a1-ac1e-4f56-aabe-efd83c0933f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03126630","created_at":"2021-01-18T15:24:22.600Z","updated_at":"2024-07-02T16:35:23.903Z","phase":"Phase 1/2","brief_title":"Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma","source_id_and_acronym":"NCT03126630","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • MSLN","pipe":" | ","alterations":" PD-L1 expression • MSLN expression","tags":["PD-L1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • anetumab ravtansine (BAY 94-9343) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 10/04/2018","start_date":" 10/04/2018","primary_txt":" Primary completion: 07/08/2023","primary_completion_date":" 07/08/2023","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2024-01-10"},{"id":"bf40d4c1-dcd3-4943-b816-d258ac3bd571","acronym":"","url":"https://clinicaltrials.gov/study/NCT05508334","created_at":"2022-08-19T17:10:11.271Z","updated_at":"2024-07-02T16:35:23.981Z","phase":"Phase 1","brief_title":"A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT05508334","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e misitatug blivedotin (RC88)"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 01/30/2023","start_date":" 01/30/2023","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-01-10"},{"id":"afcec8a4-0dae-4657-8947-be495c4de8d2","acronym":"ARCS-Multi","url":"https://clinicaltrials.gov/study/NCT03102320","created_at":"2021-01-18T15:17:05.990Z","updated_at":"2025-02-25T15:53:43.857Z","phase":"Phase 1b","brief_title":"Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors","source_id_and_acronym":"NCT03102320 - ARCS-Multi","lead_sponsor":"Bayer","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • anetumab ravtansine (BAY 94-9343)"],"overall_status":"Completed","enrollment":" Enrollment 173","initiation":"Initiation: 05/26/2017","start_date":" 05/26/2017","primary_txt":" Primary completion: 09/16/2020","primary_completion_date":" 09/16/2020","study_txt":" Completion: 07/26/2021","study_completion_date":" 07/26/2021","last_update_posted":"2022-06-30"},{"id":"f6ee17ab-5c37-4b9b-bd5b-1e4de5185e91","acronym":"","url":"https://clinicaltrials.gov/study/NCT03023722","created_at":"2021-01-18T14:52:45.385Z","updated_at":"2025-02-25T17:23:25.991Z","phase":"Phase 2","brief_title":"Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer","source_id_and_acronym":"NCT03023722","lead_sponsor":"Yale University","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anetumab ravtansine (BAY 94-9343)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 05/11/2017","start_date":" 05/11/2017","primary_txt":" Primary completion: 08/06/2019","primary_completion_date":" 08/06/2019","study_txt":" Completion: 12/11/2019","study_completion_date":" 12/11/2019","last_update_posted":"2021-10-28"},{"id":"ac6ec01d-b71d-4682-9e1d-f6ff962816a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01439152","created_at":"2021-01-18T05:57:41.754Z","updated_at":"2025-02-25T17:19:27.903Z","phase":"Phase 1","brief_title":"Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.","source_id_and_acronym":"NCT01439152","lead_sponsor":"Bayer","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anetumab ravtansine (BAY 94-9343)"],"overall_status":"Completed","enrollment":" Enrollment 148","initiation":"Initiation: 09/07/2011","start_date":" 09/07/2011","primary_txt":" Primary completion: 12/31/2016","primary_completion_date":" 12/31/2016","study_txt":" Completion: 07/30/2019","study_completion_date":" 07/30/2019","last_update_posted":"2021-07-09"},{"id":"acff4e6b-c1c6-4653-bd5d-45a3bd8b6bce","acronym":"","url":"https://clinicaltrials.gov/study/NCT02696642","created_at":"2021-01-29T07:11:49.765Z","updated_at":"2025-02-25T17:08:39.658Z","phase":"Phase 1","brief_title":"Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment","source_id_and_acronym":"NCT02696642","lead_sponsor":"Bayer","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anetumab ravtansine (BAY 94-9343)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 04/14/2016","start_date":" 04/14/2016","primary_txt":" Primary completion: 07/31/2018","primary_completion_date":" 07/31/2018","study_txt":" Completion: 08/19/2019","study_completion_date":" 08/19/2019","last_update_posted":"2021-07-09"},{"id":"fd0b0766-02cf-417f-b812-6dc78ce873ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT02610140","created_at":"2021-01-29T07:11:14.871Z","updated_at":"2025-02-25T15:42:45.006Z","phase":"Phase 2","brief_title":"Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)","source_id_and_acronym":"NCT02610140","lead_sponsor":"Bayer","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pemetrexed • vinorelbine tartrate • anetumab ravtansine (BAY 94-9343)"],"overall_status":"Completed","enrollment":" Enrollment 248","initiation":"Initiation: 12/03/2015","start_date":" 12/03/2015","primary_txt":" Primary completion: 05/31/2017","primary_completion_date":" 05/31/2017","study_txt":" Completion: 09/06/2019","study_completion_date":" 09/06/2019","last_update_posted":"2020-11-04"},{"id":"ff8e88df-126d-488f-a48d-40c230f71a19","acronym":"","url":"https://clinicaltrials.gov/study/NCT02884726","created_at":"2021-01-29T07:13:06.696Z","updated_at":"2024-07-02T16:36:47.958Z","phase":"Phase 1","brief_title":"Phase 1 Study of Mesothelin-ADC","source_id_and_acronym":"NCT02884726","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BMS-986148"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 10/14/2016","start_date":" 10/14/2016","primary_txt":" Primary completion: 09/06/2017","primary_completion_date":" 09/06/2017","study_txt":" Completion: 09/06/2017","study_completion_date":" 09/06/2017","last_update_posted":"2020-03-19"},{"id":"5aa8d102-2855-40de-9718-f6d3ba795d75","acronym":"","url":"https://clinicaltrials.gov/study/NCT02639091","created_at":"2021-01-18T12:50:14.208Z","updated_at":"2025-02-25T17:08:34.139Z","phase":"Phase 1","brief_title":"Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors","source_id_and_acronym":"NCT02639091","lead_sponsor":"Bayer","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK translocation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • pemetrexed • anetumab ravtansine (BAY 94-9343)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 02/03/2016","start_date":" 02/03/2016","primary_txt":" Primary completion: 05/23/2018","primary_completion_date":" 05/23/2018","study_txt":" Completion: 10/17/2019","study_completion_date":" 10/17/2019","last_update_posted":"2019-11-07"},{"id":"c2ebdc67-0d03-482c-9a55-4869e375c26d","acronym":"PAEMCMPAST","url":"https://clinicaltrials.gov/study/NCT03615313","created_at":"2021-01-17T17:13:11.016Z","updated_at":"2024-07-02T16:37:08.261Z","phase":"Phase 1/2","brief_title":"PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor","source_id_and_acronym":"NCT03615313 - PAEMCMPAST","lead_sponsor":"Shanghai Cell Therapy Research Institute","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • BZDS1901"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 08/06/2018","start_date":" 08/06/2018","primary_txt":" Primary completion: 08/03/2020","primary_completion_date":" 08/03/2020","study_txt":" Completion: 12/03/2020","study_completion_date":" 12/03/2020","last_update_posted":"2018-08-03"},{"id":"927d067b-a2c8-45e8-b48f-882fec92e64b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02485119","created_at":"2021-01-18T11:58:19.477Z","updated_at":"2025-02-25T17:08:10.448Z","phase":"Phase 1","brief_title":"Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies","source_id_and_acronym":"NCT02485119","lead_sponsor":"Bayer","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anetumab ravtansine (BAY 94-9343)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 08/14/2015","start_date":" 08/14/2015","primary_txt":" Primary completion: 04/28/2017","primary_completion_date":" 04/28/2017","study_txt":" Completion: 07/04/2017","study_completion_date":" 07/04/2017","last_update_posted":"2018-06-04"}]